Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TLK286 + docetaxel
- Development stage
- Phase 2
- Lead developer
- Telik
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
TLK286 (also known as Telcyta) is an investigational antitumor prodrug developed by Telik. It is designed to be selectively activated in tumor cells that overexpress glutathione S-transferase P1-1 (GSTP1), an enzyme associated with drug resistance and poor prognosis in various solid tumors, including ovarian, lung, breast, gastrointestinal, and head and neck cancers. Upon activation by GSTP1 within the tumor cell, TLK286 initiates apoptosis specifically in these cancer cells[1]. Docetaxel is a well-established taxane-class chemotherapeutic agent that works by promoting microtubule assembly and stabilizing them against depolymerization, thereby inhibiting cell division and inducing apoptosis in rapidly dividing cancer cells[2][4]. The combination of TLK286 with docetaxel has been investigated clinically for enhanced efficacy against cancers such as non-small cell lung cancer (NSCLC) and ovarian cancer[1].
- Brand names
- TaxotereDocefrez
- Other names
- TLK 286TLK286TLK-286Telcyta
02
Targets
GSTP1 (Glutathione S-transferase P)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on TLK286 + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TLK286 + docetaxel.